Charlotte Graham

Broad Institute — United States

Medicine · Health Sciences

20h-index1.8kcitations73works5.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(43), Viral Infectious Diseases and Gene Expression in Insects(10), Biosimilars and Bioanalytical Methods(10), Advancements in Semiconductor Devices and Circuit Design(6), Acute Lymphoblastic Leukemia research(6)

Publications71 total

Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide—A Prospective Study on Behalf of the EBMT Transplant Complications Working Party
Cancers·2025Open Access
Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma
Blood·2025
First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance
Blood·2025Open Access
The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma
Blood·2025
365 Single-cell transcriptional profiles of cilta-cel and ide-cel associate with response in multiple myeloma
Regular and Young Investigator Award Abstracts·2025Open Access
Genomic correlates of clinical CAR-T cell activity
2025Open Access
First-in-Human Phase 1 Trial of Trimeric APRIL (TriPRIL) CAR-T Cells in Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT
Bone Marrow Transplantation·2025
IFN-γ–resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models
Science Translational Medicine·2025· 10 citedOpen Access
GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party
Universität Zürich, ZORA·2025Open Access
GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party
Leukemia·2025· 3 citedOpen Access
The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT
Bone Marrow Transplantation·2025· 5 citedOpen Access
Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee
Bone Marrow Transplantation·2025· 4 cited
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
The Lancet Oncology·2025· 29 cited
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment
Blood·2025· 12 citedOpen Access
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma
Blood Advances·2025· 7 citedOpen Access
Long-Term Neuropsychiatric Outcomes after CD19 and BCMA Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Retrospective Analysis of Real-World Data from Over 2200 Patients
SSRN Electronic Journal·2025Open Access
Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Transplant Complications Working Party
Bone Marrow Transplantation·2024· 1 citedOpen Access
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML
Blood·2024· 21 citedOpen Access
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
Leukemia·2024· 9 cited
page 1 of 4Next →

Frequent Co-authors

Marcela V. Maus(21), Reuben Benjamin(16), Matthew J. Frigault(14), Agnieszka Jóźwik(13), Mark B. Leick(11), Kathleen Gallagher(8), Zinaida Perić(8), Olaf Penack(8), Nitin Jain(7), Mohamad Mohty(7), Sandra Dupouy(7), Orla Stewart(7), Won‐Ho Lee(7), Deborah Yallop(6), Nicolas Boissel(6), Svetlana Balandraud(6), Maria Almena-Carrasco(6), Trisha R. Berger(6), William Boreland(6), Hélène Schoemans(6)